ERBB2 and breast carcinoma: The discovery of HER2 led to the development and approval of the first HER2-targeted therapy, trastuzumab.6 It is now clear that the advent and routine use of targeted anti-HER2 therapies have dramatically improved disease control and survival in patients with HER2-positive breast cancer.